RBC Life Sciences Announces 2009 Year End Results
11 3월 2010 - 10:00PM
PR Newswire (US)
IRVING, Texas, March 11 /PRNewswire-FirstCall/ -- (RBC Life
Sciences: OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a
provider of proprietary nutritional supplements, wound care and
pain management products, reported today company-wide net sales of
$24.9 million for the year ended December 31, 2009, compared to net
sales of $30.4 million for the same period during 2008. The company
also reported a net loss of $335,000, or $0.02 per diluted share,
during 2009, compared to net earnings of $1.6 million, or $0.07 per
diluted share, during 2008. "In 2009, our international licensees
were hobbled by the global economy overseas, which contributed
disproportionately to our decline in sales," said RBC Life Sciences
President and CEO John W. Price. "We did, however, see sales in
this channel begin to increase late in the year as global economic
conditions also began to show signs of improvement. A bright spot
in 2009 was the growth of our North American network marketing
base. Sales domestically grew more than 4% percent in 2009 compared
to the previous year." Mr. Price also said that RBC Life Sciences
is now compliant with industry-wide, FDA-required Good
Manufacturing Practices (GMP). "The company invested substantial
resources to achieve GMP compliance during 2009 and will continue
to do so annually to maintain our GMP status," said Mr. Price. GMPs
ensure that companies adhere to practices that promote product
safety, quality and efficacy. About RBC Life SciencesThrough U.S.
and Canadian subsidiaries, RBC Life Sciences develops, manufactures
and markets high-quality nutritional supplements and personal care
products under its RBC Life brand to a growing population of
consumers seeking wellness and a healthy lifestyle. MPM Medical,
the company's medical products subsidiary, develops and markets to
health care professionals in the United States proprietary
prescription and nonprescription products for advanced wound care
and pain management. All products are tested for quality assurance
in-house, and by outside independent laboratories, to comply with
regulations in the U.S. and in more than thirty countries in which
the products are distributed. For more information, visit the
company's Web site at http://www.rbclifesciences.com/. The
statements above, other than statements of historical fact, may be
forward-looking. Actual events will be dependent upon a number of
factors and risks including, but not limited to, changes in plans
by the Company's management, delays or problems in production,
changes in the regulatory process, changes in market trends, and a
number of other factors and risks described from time to time in
the Company's filings with the Securities and Exchange Commission.
RBC Life Sciences, Inc. Summary Results of Operations (in
thousands, except per share data) (unaudited) Years Ended December
31, ------------------------ 2009 2008 ---- ---- Net sales $24,925
$30,409 Gross profit 12,802 15,494 Operating profit (loss) (160)
2,852 Earnings (loss) before income taxes (324) 2,677 Provision for
income taxes 11 1,061 Net earnings (loss) (335) 1,616 Earnings
(loss) per share - basic $(0.02) $0.08 Earnings (loss) per share -
diluted (0.02) 0.07 Weighted average shares outstanding - basic
21,921 21,465 Weighted average shares outstanding - diluted 21,921
22,839 RBC Life Sciences, Inc. Condensed Balance Sheets (in
thousands) (unaudited) December 31, December 31, ------------
------------ 2009 2008 ---- ---- Assets Cash and cash equivalents
$3,972 $4,973 Inventories 5,344 5,707 Other current assets 1,914
2,245 ----- ----- Total current assets 11,230 12,925 Other assets
7,383 6,841 ----- ----- Total assets $18,613 $19,766 =======
======= Liabilities and shareholders' equity Accounts payable and
accrued liabilities $2,729 $3,228 Deferred revenue 3,669 4,279
Other current liabilities 156 144 --- --- Total current liabilities
6,554 7,651 Other liabilities 2,840 2,728 Shareholders' equity
9,219 9,387 ----- ----- Total liabilities and shareholders' equity
$18,613 $19,766 ======= ======= DATASOURCE: RBC Life Sciences, Inc.
CONTACT: Steve Brown of RBC Life Sciences,
+1-972-893-4000,steve.brown@rbclifesciences.com Web Site:
http://www.rbclifesciences.com/
Copyright
Royal Bank Can (LSE:RBC)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Royal Bank Can (LSE:RBC)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024